GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » General and Admin. Expense

CTOR (Citius Oncology) General and Admin. Expense : $ Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Citius Oncology's General and Admin. Expense for the six months ended in Sep. 2024 was $15.65 Mil. Citius Oncology does not have enough years/quarters to calculate the General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024.


Citius Oncology General and Admin. Expense Historical Data

The historical data trend for Citius Oncology's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology General and Admin. Expense Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
General and Admin. Expense
1.43 7.88 15.65

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
General and Admin. Expense 1.43 7.88 15.65

Citius Oncology General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.


Citius Oncology General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Citius Oncology's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Oncology Business Description

Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.